Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept immunological assay evaluation after StroVac vaccination
2026-527508-25-00Phase 4Authorised
- Sponsor
- Strathmann
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of StroVac in urinary tract infection (UTI), sponsored by Strathmann. Primary endpoints: Change in patient-specific IgG against target bacterial strains and Change in patient-specific IgA against target bacterial strains. Planned start Oct 2026; status: authorised.
02
Drugs
StroVac
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2026-527508-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527508-25-00.